Last updated: June 21, 2026
Litigation Summary and Analysis for Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:16-cv-01167
Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., case number 1:16-cv-01167, is a U.S. Hatch-Waxman patent litigation matter brought by Astellas against Zydus. The case was filed in 2016 and is docketed as 1:16-cv-01167. A litigation summary that ties specific asserted patents, claims, filing and service dates, Markman rulings, claim constructions, trial/settlement terms, and post-judgment status cannot be produced from the information provided.
What patents were asserted in Astellas v. Zydus 1:16-cv-01167?
Featured snippet answer: The asserted patent list, patent numbers, and claim sets are not provided.
Which Orange Book patents were targeted?
Featured snippet answer: The Orange Book code entries and the specific patents tied to the NDA/ANDA product in suit are not provided.
Were method-of-use, formulation, or manufacturing patents at issue?
Featured snippet answer: The patent type mix (formulation, method-of-use, process, polymorph, salt, or device) is not provided.
What claims and theories did Astellas bring against Zydus?
Featured snippet answer: The complaint’s causes of action and the infringement theories (literal infringement, doctrine of equivalents, induced/contributory infringement) are not provided.
Did Astellas allege willful infringement?
Featured snippet answer: Willfulness allegations are not provided.
Did Zydus challenge validity via invalidity counterclaims?
Featured snippet answer: Specific invalidity grounds (anticipation, obviousness, indefiniteness, lack of written description/enablement, improper inventorship) are not provided.
What was the procedural timeline for 1:16-cv-01167?
Featured snippet answer: The docket timeline (procedural steps, key filings, and court dates) is not provided.
When were the complaint and answers filed?
Featured snippet answer: Filing dates for the complaint, service date, and Zydus answer dates are not provided.
Were there Markman proceedings and claim construction orders?
Featured snippet answer: Markman schedule and any claim construction decisions are not provided.
Did the case reach trial or resolve on summary judgment?
Featured snippet answer: Trial and dispositive motion outcomes are not provided.
What Paragraph IV certifications did Zydus make in the ANDA?
Featured snippet answer: The Orange Book listing(s) and the paragraph IV certification details (to which patents, carve-outs, and dates) are not provided.
Was there a first ANDA filer or earlier Paragraph IV filer?
Featured snippet answer: Launch-risk timing based on first-filer status is not provided.
Did Zydus assert a section viii statement, carve-out, or change in manufacturing?
Featured snippet answer: ANDA certification and FDA-related carve-out facts are not provided.
What was the Orange Book status of the product in dispute?
Featured snippet answer: The Orange Book listing(s) for the relevant NDA product, including patent expiry and exclusivity details, are not provided.
When did the relevant NDA patents expire?
Featured snippet answer: Specific expiration dates are not provided.
Did any exclusivities (3-year, 5-year, pediatric) extend launch?
Featured snippet answer: Exclusivity status and end dates are not provided.
How did FDA review and litigation interact in 1:16-cv-01167?
Featured snippet answer: The FDA regulatory milestones tied to the ANDA in suit are not provided.
What FDA pathway and tentative approval timing applied?
Featured snippet answer: FDA pathway (505(b)(2) vs ANDA), approval status, and tentative approval timing are not provided.
Was there an automatic 30-month stay?
Featured snippet answer: Whether a 30-month stay occurred, and if so, the effective dates, are not provided.
How strong was Astellas’s patent estate versus Zydus’s generic launch risk?
Featured snippet answer: The strength analysis depends on asserted patents, claim scope, validity posture, and outcomes, none of which are provided.
What prior art or obviousness landscape supported Astellas’s case?
Featured snippet answer: Prior art and validity arguments are not provided.
Did courts uphold or narrow key claims?
Featured snippet answer: No claim-upholding or narrowing outcomes are provided.
What settlements or consent judgments were entered?
Featured snippet answer: Settlement terms and effective dates are not provided.
Were there stipulated launch dates or “at-risk” launch carve-outs?
Featured snippet answer: No settlement provisions are provided.
Did the parties enter a licensing agreement?
Featured snippet answer: No license terms or scope (territory, royalties, patent subset) are provided.
What is the current litigation status and who controls the remaining risk?
Featured snippet answer: Current posture (pending, dismissed, settled with final judgment, appeal) is not provided.
Was there an appeal to the Federal Circuit?
Featured snippet answer: Appellate history is not provided.
Are there remaining related cases or continuations?
Featured snippet answer: Related dockets are not provided.
Key Takeaways
- The docket designation 1:16-cv-01167 is identified, but the provided inputs do not include the specific asserted patents, Orange Book entries, procedural milestones, claim constructions, or outcomes.
- Without those case-specific details, a defensible litigation summary and risk analysis for Astellas versus Zydus cannot be completed.
FAQs
- What patents were listed in the Orange Book for the NDA at issue in 1:16-cv-01167?
- Which claims did Astellas allege were infringed by Zydus’s ANDA product?
- What were the court’s claim construction rulings in Astellas v. Zydus, 1:16-cv-01167?
- Did the case end in a settlement, consent judgment, or dismissal, and what launch terms were included?
- Was a 30-month stay imposed, and how did it affect the FDA approval timeline?
References
- U.S. District Court docket, Astellas Pharma Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:16-cv-01167.
